Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model

C P Mallett; L VanDeVerg; H H Collins; T L Hale

doi:10.1016/0264-410x(93)90016-q

Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model

Vaccine. 1993;11(2):190-6. doi: 10.1016/0264-410x(93)90016-q.

Authors

C P Mallett¹, L VanDeVerg, H H Collins, T L Hale

Affiliation

¹ Department of Enteric Infections, Walter Reed Army Institute of Research, Washington, DC 20307-5100.

PMID: 8438617
DOI: 10.1016/0264-410x(93)90016-q

Abstract

Five Shigella vaccine candidates (EcSf2a-1, EcSf2a-2, Sfl124, T32-Istrati and SMD) were tested for safety and efficacy in Balb/cJ mice using an intranasal challenge model. Experiments in this model suggest that (i) the relative attenuation of vaccines can be determined in mice by intranasal inoculation, (ii) all vaccines tested elicited antibacterial mucosal immunity protecting against pulmonary infection with Shigella flexneri 2a, (iii) protection was associated with serum IgA and/or IgG antibody recognizing the 2a somatic antigen.

MeSH terms

Administration, Intranasal
Animals
Antibodies, Bacterial / biosynthesis*
Antibodies, Bacterial / immunology
Bacterial Vaccines* / administration & dosage
Bacterial Vaccines* / immunology
Bacterial Vaccines* / toxicity
Drug Evaluation, Preclinical
Dysentery, Bacillary / prevention & control
Enzyme-Linked Immunosorbent Assay
Female
Immunoglobulin Isotypes / biosynthesis
Immunoglobulin Isotypes / immunology
Mice
Mice, Inbred BALB C / immunology
Pneumonia / microbiology
Pneumonia / prevention & control
Safety
Shigella flexneri / immunology*

Substances

Antibodies, Bacterial
Bacterial Vaccines
Immunoglobulin Isotypes